|
1
|
Evans DG and Howell A: Breast cancer
risk-assessment models. Breast Cancer Res. 9:2132007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ilyas M: Wnt signalling and the
mechanistic basis of tumour development. J Pathol. 205:130–144.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
King TD, Suto MJ and Li Y: The
Wnt/b-catenin signaling pathway: A potential therapeutic target in
the treatment of triple negative breast cancer. J Cell Biochem.
113:13–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hardie DG: Minireview: The AMP-activated
protein kinase cascade: The key sensor of cellular energy status.
Endocrinology. 144:5179–5183. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Richter EA and Ruderman NB: AMPK and the
biochemistry of exercise: Implications for human health and
disease. Biochem J. 418:261–275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomas G and Hall MN: TOR signalling and
control of cell growth. Curr Opin Cell Biol. 9:782–787. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vazquez-Martin A, Oliveras-Ferraros C,
Lopez-Bonet E and Menendez JA: AMPK: Evidence for an energy-sensing
cytokinetic tumor suppressor. Cell Cycle. 8:3679–3683. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carretero J, Medina PP, Blanco R, Smit L,
Tang M, Roncador G, Maestre L, Conde E, Lopez-Rios F, Clevers HC
and Sanchez-Cespedes M: Dysfunctional AMPK activity, signalling
through mTOR and survival in response to energetic stress in
LKB1-deficient lung cancer. Oncogene. 26:1616–1625. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Corton JM, Gillespie JG, Hawley SA and
Hardie DG: 5-aminoimidazole-4-carboxamide ribonucleoside. A
specific method for activating AMP-activated protein kinase in
intact cells? Eur J Biochem. 229:558–565. 1995.PubMed/NCBI
|
|
12
|
Yung MM, Chan DW, Liu VW, Yao KM and Ngan
HY: Activation of AMPK inhibits cervical cancer cell growth through
AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 13:3272013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo Z, Zang M and Guo W: AMPK as a
metabolic tumor suppressor: Control of metabolism and cell growth.
Future Oncol. 6:457–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin-Belmonte F and Perez-Moreno M:
Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer.
12:23–38. 2011.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–428. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Metcalfe C, Ibrahim AE, Graeb M, de la
Roche M, Schwarz-Romond T, Fiedler M, Winton DJ, Corfield A and
Bienz M: Dvl2 promotes intestinal length and neoplasia in the
ApcMin mouse model for colorectal cancer. Cancer Res. 70:6629–6638.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Uematsu K, He B, You L, Xu Z, McCormick F
and Jablons DM: Activation of the Wnt pathway in non small cell
lung cancer: Evidence of dishevelled overexpression. Oncogene.
22:7218–7221. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uematsu K, Kanazawa S, You L, He B, Xu Z,
Li K, Peterlin BM, McCormick F and Jablons DM: Wnt pathway
activation in mesothelioma: Evidence of Dishevelled overexpression
and transcriptional activity of beta-catenin. Cancer Res.
63:4547–4551. 2003.PubMed/NCBI
|
|
22
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu SY, Chan DW, Liu VW and Ngan HY:
Inhibition of cervical cancer cell growth through activation of
upstream kinases of AMP-activated protein kinase. Tumour Biol.
30:80–85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hawley SA, Pan DA, Mustard KJ, Ross L,
Bain J, Edelman AM, Frenguelli BG and Hardie DG:
Calmodulin-dependent protein kinase kinase-beta is an alternative
upstream kinase for AMP-activated protein kinase. Cell Metab.
2:9–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Canto C, Gerhart-Hines Z, Feige JN,
Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P and Auwerx
J: AMPK regulates energy expenditure by modulating NAD+ metabolism
and SIRT1 activity. Nature. 458:1056–1060. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guigas B, Sakamoto K, Taleux N, Reyna SM,
Musi N, Viollet B and Hue L: Beyond AICA riboside: In search of new
specific AMP-activated protein kinase activators. IUBMB Life.
61:18–26. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mizutani K, Miyamoto S, Nagahata T,
Konishi N, Emi M and Onda M: Upregulation and overexpression of
DVL1, the human counterpart of the Drosophila dishevelled gene, in
prostate cancer. Tumori. 91:546–551. 2005.PubMed/NCBI
|
|
28
|
Nagahata T, Shimada T, Harada A, Nagai H,
Onda M, Yokoyama S, Shiba T, Jin E, Kawanami O and Emi M:
Amplification, up-regulation and over-expression of DVL-1, the
human counterpart of the Drosophila disheveled gene, in primary
breast cancers. Cancer Sci. 94:515–518. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miyoshi Y, Iwao K, Nagasawa Y, Aihara T,
Sasaki Y, Imaoka S, Murata M, Shimano T and Nakamura Y: Activation
of the beta-catenin gene in primary hepatocellular carcinomas by
somatic alterations involving exon 3. Cancer Res. 58:2524–2527.
1998.PubMed/NCBI
|
|
30
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of
beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Holloway KR, Calhoun TN, Saxena M, Metoyer
CF, Kandler EF, Rivera CA and Pruitt K: SIRT1 regulates Dishevelled
proteins and promotes transient and constitutive Wnt signaling.
Proc Natl Acad Sci USA. 107:9216–9221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen Z, Wen XF, Lan F, Shen ZZ and Shao
ZM: The tumor suppressor gene LKB1 is associated with prognosis in
human breast carcinoma. Clin Cancer Res. 8:2085–2090.
2002.PubMed/NCBI
|
|
33
|
Zhou J, Huang W, Tao R, Ibaragi S, Lan F,
Ido Y, Wu X, Alekseyev YO, Lenburg ME, Hu GF and Luo Z:
Inactivation of AMPK alters gene expression and promotes growth of
prostate cancer cells. Oncogene. 28:1993–2002. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gonzalez-Angulo AM and Meric-Bernstam F:
Metformin: A therapeutic opportunity in breast cancer. Clin Cancer
Res. 16:1695–1700. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takatani T, Minagawa M, Takatani R,
Kinoshita K and Kohno Y: AMP-activated protein kinase attenuates
Wnt/β-catenin signaling in human osteoblastic Saos-2 cells. Mol
Cell Endocrinol. 339:114–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhuang Y and Miskimins WK: Cell cycle
arrest in Metformin treated breast cancer cells involves activation
of AMPK, downregulation of cyclin D1, and requires p27Kip1 or
p21Cip1. J Mol Signal. 3:182008. View Article : Google Scholar : PubMed/NCBI
|
